Developing a Raman spectroscopy-based tool to stratify patient response to pre-operative radiotherapy in rectal cancer. Issue 2 (12th November 2020)

• Record Type: Journal Article
• Authors: Kirkby, Chloe J.; Gala de Pablo, Julia; Tinkler-Hundal, Emma; Wood, Henry M.; Evans, Stephen D.; West, Nicholas P.
• Is Part Of: Analyst. Volume 146:Issue 2(2021)
• Page Start: 581
• Page End: 589
• Publication Date: 2020-11-12
• Subjects: Chemistry, Analytic -- Periodicals; 543
• DOI: 10.1039/d0an01803a
• Languages: English
• ISSNs: 0003-2654

Abstract

Abstract : The use of Raman spectroscopy to stratify rectal cancer patient response to pre-operative radiotherapy, using routine pre-treatment biopsy samples. Abstract : Rectal cancer patients frequently receive pre-operative radiotherapy (RT), prior to surgical resection. However, colorectal cancer is heterogeneous and the degree of tumour response to pre-operative RT is highly variable. There are currently no clinically approved methods of predicting response to RT, and a significant proportion of patients will show no clinical benefit, despite enduring the side-effects. We evaluated the use of Raman spectroscopy (RS), a non-destructive technique able to provide the unique chemical fingerprint of tissues, as a potential tool to stratify patient response to pre-operative RT. Raman measurements were obtained from the formalin-fixed, paraffin-embedded (FFPE) pre-treatment biopsy specimens of 20 rectal cancer patients who received pre-operative RT. A principal component analysis and linear discriminant analysis algorithm was able to classify patient response to pre-operative RT as good or poor, with an accuracy of 86.04 ± 0.14% (standard error). Patients with a good response to RT showed greater contributions from protein-associated peaks, whereas patients who responded poorly showed greater lipid contributions. These results demonstrate that RS is able to reliably classify tumour response to pre-operative RT from FFPE biopsies and highlights its potential to guide personalised cancer patient treatment.